Foghorn therapeutics announces clinical data from phase 1 study of fhd-286 in metastatic uveal melanoma

- clinical data support safety and tolerability profile of fhd-286, a highly potent, - selective, allosteric, oral, small molecule inhibitor of brg1/brm - clinical activity observed in late-line metastatic uveal melanoma includes nine patients with stable disease and one patient with a confirmed partial response - foghorn does not plan to advance fhd-286 in uveal melanoma - foghorn anticipates initiating a fhd-286 combination study in relapsed/refractory aml during the third quarter of 2023 cambridge, mass., june 28, 2023 (globe newswire) -- foghorn® therapeutics inc. (nasdaq: fhtx), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious disease by correcting abnormal gene expression, today announced data from the phase 1 dose escalation safety study of fhd-286 in metastatic uveal melanoma (mum).
FHTX Ratings Summary
FHTX Quant Ranking